The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether summary of findings. Surgery (percutaneous wire fixation) changes serious adverse events (typically more serious complications) ( compared with not surgery (cast only) (very low certainty).
Summary of findings table ‐ Fitusiran prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).
Summary of findings table ‐ Fitusiran prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).
Summary of findings table ‐ Emicizumab prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).
Summary of findings: insulin detemir showed no clear difference in serious adverse events (n/N) compared with insulin glargine (low certainty).
Summary of findings: insulin detemir showed no clear difference in serious adverse events (n/N) compared with NPH insulin (moderate certainty).
Summary of findings table ‐ More time showed no clear difference in serious adverse events/death compared with less time (low certainty).
Summary of findings: insulin glargine showed no clear difference in serious adverse events (n/N) compared with NPH insulin (moderate certainty).
Summary of findings: insulin degludec showed no clear difference in serious adverse events (n/N) compared with insulin detemir (low certainty).
Summary of findings: insulin degludec showed no clear difference in serious adverse events (n/N) compared with insulin glargine (low certainty).
Summary of findings: bevacizumab showed no clear difference in serious ocular adverse events at 1 year compared with ranibizumab (moderate certainty).
Summary of findings table ‐ Emicizumab 1.5 mg/kg once weekly showed no clear difference in all adverse events compared with emicizumab 3.0 mg/kg every 2 weeks (moderate certainty).
Summary of findings: bevacizumab showed no clear difference in serious systemic adverse events at 1 yearb compared with ranibizumab (moderate certainty).
Summary of findings table ‐ Fitusiran prophylaxis showed no clear difference in serious adverse events compared with on‐demand therapy (moderate certainty).
Summary of findings table ‐ Emicizumab prophylaxis showed no clear difference in serious adverse events compared with on‐demand therapy (moderate certainty).
Summary of findings table ‐ Emicuzimab 1.5 mg/kg weekly prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).
The review found no eligible studies for this question.